Skip to content

The Effectiveness of Antibacterial Therapeutic Clothing Based on Silver or Chitosan as Compared With Non-antibacterial Therapeutic Clothing in Patients With Moderate to Severe Atopic Dermatitis

Pragmatic Randomized Controlled Multi Center Trial Comparing the Effectiveness of Antibacterial Therapeutic Clothing Based on Silver or Chitosan as Compared With Non-antibacterial Therapeutic Clothing in Patients With Moderate to Severe Atopic Dermatitis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04297215
Acronym
ABC project
Enrollment
165
Registered
2020-03-05
Start date
2020-03-17
Completion date
2023-01-01
Last updated
2020-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

Atopic dermatitis, Staphylococcus aureus, Therapeutical clothing, Anti-infective agents

Brief summary

Since 2000 therapeutic clothing or functional textiles based on silver or chitosan as antibacterial agents were introduced as therapeutics of atopic dermatitis (AD). These agents aim to reduce skin colonization with Staphylococcus (S.) aureus. S. aureus induces further dysregulation of the inflammatory process and increased colonization with S. aureus is correlated with increased AD severity. Based on the theoretical mode of action and clinical experience, we assume a higher effectiveness of antimicrobial therapeutic clothing compared to control therapeutic clothing on reducing AD severity. The goal of this study is to assess the effectiveness of antibacterial clothing based on silver or chitosan on the doctor-reported AD severity in patients with moderate to severe AD. Secondary goals are to retrieve information about the effect of antimicrobial clothing on clinical symptoms, quality of life, S. aureus colonization, AD medication use and the satisfaction regarding the clothing.

Detailed description

This is a multi-center, double-blind, randomized controlled trial. Patients will be randomized in a 1:1:1 fashion to either therapeutic clothing without antimicrobial agents, antimicrobial therapeutic clothing based on chitosan or antimicrobial clothing based on silver for 12 months.

Interventions

DEVICEDermaCura® Chitosan based antimicrobial therapeutic clothing

DermaCura® antimicrobial therapeutic clothing (D&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL® The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.

DEVICEBinamed® silver based antimicrobial therapeutic clothing

The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent. The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.

DEVICEBinamed® therapeutic clothing without antimicrobial agents

The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin. The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
UMC Utrecht
CollaboratorOTHER
St. Antonius Hospital
CollaboratorOTHER
ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
BAP Medical
CollaboratorUNKNOWN
D&M B.V.
CollaboratorUNKNOWN
DeclaCare
CollaboratorUNKNOWN
University Medical Center Groningen
CollaboratorOTHER
Erasmus Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No

Inclusion criteria

* Atopic dermatitis diagnosed according to the criteria of Williams (Williams 1994) * Atopic dermatitis severity according to EASI at t = 0: \> 6.0.

Exclusion criteria

* Treatment with oral antibiotics until 1 month before inclusion; * Treatment with topical antibiotics until 1 week before inclusion; * Treatment with systemic immunosuppressive agents or light therapy until 1 month before inclusion; * Treatment with (antibacterial) therapeutic clothing until 1 month before inclusion; * Impaired kidney function (anamnestic assessed) * Pregnancy or pregnancy wish during study (anamnestic assessed) * Hypersensitivity to silver (anamnestic assessed) * Evidence of past non-compliance to treatments or appointment

Design outcomes

Primary

MeasureTime frameDescription
Change in the Eczema Area and Severity Index (EASI)Two weeks for baseline, baseline, 1 month, 3 months 6 months and 12 monthsChange in disease severity measured by the EASI between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. Minimum score is 0, maximum score is 72. A higher score indicates more sever eczema

Secondary

MeasureTime frameDescription
Change in S. Aureus colonizationBaseline, 1 month, 3 months 6 months and 12 monthsChange in S. aureus colonization between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months
Change in the Patient Oriented Eczema Measure (POEM)Baseline, 1 month, 3 months 6 months and 12 monthsChange in POEM or POEM for proxy completion in the case of children up to 10 years of age by their parents between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. The POEM is a validated and standardized patient questionnaire.
Change in Patient global assessment (PGA) of disease severityBaseline, 1 month, 3 months 6 months and 12 monthsChange in PGA severity of the disease between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. This is a standardized patient questionnaire. The minimum score is 0, the maximum score is 4.
Change in the Dermatology Life Quality Index (DLQI)Baseline, 1 month, 3 months 6 months and 12 monthsChange in DLQI between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. Minimum score is 0, maximum score is 30. A higher score indicates more impact on quality of life. This outcome measure is assessed in patient \>16 years old. The DLQI is a validated and standardized patient questionnaire.
Change in the Child Dermatology Life Quality Index (CDLQI)Baseline, 1 month, 3 months 6 months and 12 monthsChange in CDLQI between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. Minimum score is 0, maximum score is 30. A higher score indicates more impact on quality of life. This outcome measure is assessed in patient 4-16 years old. The CDLQI is a validated and standardized patient questionnaire.
Change in the Infant Dermatology Life Quality Index (IDLQI)Baseline, 1 month, 3 months 6 months and 12 monthsChange in IDLQI between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. Minimum score is 0, maximum score is 30. A higher score indicates more impact on quality of life. his outcome measure is assessed in patient \<4 years old. The IDLQI is a validated and standardized patient questionnaire.
Change on the visual analogue scale (0-100 mm) for itch (VAS for itch)Baseline, 1 month, 3 months 6 months and 12 monthsChange in degree of itching, expressed on a visual analogue scale (0-100 mm), between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. Minimum score is 0, maximum score is 100mm. A higher score indicates more itch.
Change on the visual analogue scale (0-100 mm) for sleep disturbance (VAS for sleep disturbance)Baseline, 1 month, 3 months 6 months and 12 monthsChange in degree of sleep disturbance, expressed on a VAS (0-100 mm), between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. Minimum score is 0, maximum score is 100mm. A higher score indicates more sleep disturbance.
Change on the visual analogue scale (0-100 mm) for pain (VAS for pain)Baseline, 1 month, 3 months 6 months and 12 monthsDifference in degree of pain, expressed on a VAS (0-100 mm), between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. Minimum score is 0, maximum score is 100mm. A higher score indicates more pain.
Use emollientsThrough study completion, 1 yearDifference in emollients use between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) is assessed weekly over 12 months. A patient questionnaire with two items (daily application frequency and number of days per week) will be used to assess this outcome.
Use of antibioticsThrough study completion, 1 yearDifference in total use of antibiotics between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) is assessed over 12 months. A weekly patient questionnaire with two items (dose and number of days) will be used to assess this outcome.
Change in global assessment of degree of impetiginisationBaseline, 1 month, 3 months 6 months and 12 monthsChange in global assessment of degree of impetiginisation (pustules, oozing, crust formation) of dermatitis between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups), expressed as 0 - no impetiginisation, 1 - sporadic impetiginisation, 2 - mild impetiginisation, 3 - moderate impetiginisation, 4 - severe impetiginisation
Use of therapeutic clothingThrough study completion, 1 yearDifference in therapeutic clothing use between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) is assessed over 12 months. A weekly patient questionnaires with two items (number of nights worn and number of days worn) will be used to assess this outcome.
Quality-adjusted life yearBaseline, 1 month, 3 months 6 months and 12 monthsDifference in the QALYs based on EuroQol questionnaire between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months.
Recap of atopic eczema (RECAP) - a standardized questionnaire that measures (long term) AD controlBaseline, 1 month, 3 months, 6 months and 12 monthsChange in RECAP between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. RECAP is an standardized instrument (patient questionnaire) with 10 items to measure (long-term) eczema control.
Dermatitis Family Impact (DFI) - a standardized questionnaire that measures the impact of a skin disease on the family of the patientBaseline, 3 months, 6 months and 12 monthsChange in DFI on the family of the patient between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. (only in patients \<18 years). The minimum DFI score is 0 (= no impact on life of family). The maximum DFI score is 30 (= maximum effect on life of family). The DFI is a standerized patient questionnaire.
Family Dermatology Life Quality (FDLQI) - a standardized questionnaire that measures the impact of a skin disease on family membersBaseline, 3 months, 6 months and 12 monthsChange in FDLQI between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. (by parents in patients \<18 years, by partner in patients \>18 years. This questionnaire assesses impairement of the quality of life of adult family members. A higher score indicates more impairment.
Parenting Stress QuestionnaireBaseline, 3 months, 6 months and 12 monthsDifference in parenting stress between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. (Only in patients \<18 years old). A T-score \< 60 can be seen as normal, a higher score implicates clinical problems. The parenting stress questionnaire is a validated and standardized questionnaire
Quality of life (measured by the TAPCOL)Baseline, 3 months, 6 months and 12 monthsDifference in quality of life between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. The TAPCOL is validated and standardized questionnaire for children 6\< years.
Quality of life (measured by the TACQOL )Baseline, 3 months, 6 months and 12 monthsDifference in quality of life between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. The TAPQOL is a validated and standardized patient questionnaire for children (\>5 years, \<16 years)
Quality of life (measured by the TAAQOL )Baseline, 3 months, 6 months and 12 monthsDifference in quality of life between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) over 12 months. The TAAQOL is a validated and standardized patient questionnaire for patients older than 16 years old.
Change of silver excretion in urineBaseline, 1month, 3 months, 6 months and 12 monthsDifference in urinary silver excretion over time. Measured in the silver group only.
Use of topical corticosteroidsThrough study completion, 1 yearDifference in topical corticosteroid use between the clothing without antimicrobial agents (control group) and microbial growth reducing/ antimicrobial clothing based on chitosan or silver (intervention groups) is assessed over 12 months. A weekly patient questionnaire with two items (application frequency and number of days) will be used to assess this outcome.

Countries

Netherlands

Contacts

Primary ContactSuzanne G.M.A. Pasmans, Prof
s.pasmans@erasmusmc.nl+31 6 53524299

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026